Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation

This study aimed to evaluate the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion (DLI) in treating patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Twenty-six AML patients who relapsed after all...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Peng, Ni, Ming, Ma, Dan, Fang, Qin, Zhang, Yan, Li, Yanju, Huang, Yi, Chen, Ying, Chai, Xiao, Zhan, Yun, Li, Yan, Kang, Qian, Zhao, Mei, Liu, Min, Zhang, Fengqi, Huang, Shisi, Wen, Shuangshuang, Deng, Bo, Wang, Jishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720738/
https://www.ncbi.nlm.nih.gov/pubmed/34568973
http://dx.doi.org/10.1007/s00277-021-04674-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720738/
https://www.ncbi.nlm.nih.gov/pubmed/34568973
http://dx.doi.org/10.1007/s00277-021-04674-x

Ejemplares similares